A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

August 1, 2026

Conditions

Gestational Trophoblastic DiseaseGestational Trophoblastic NeoplasiaGestational Trophoblastic Tumor, Recurrent

Interventions

DRUG

Pembrolizumab

Single dose 200mg dose of Pembrolizumab given intravenously

Trial Locations (1)

RECRUITING

Imperial College Healthcare NHS Trust, London